# Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

> **NCT05027932** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 45 (actual)

## Conditions studied

- Influenza

## Interventions

- **OTHER:** IN Placebo
- **OTHER:** IM Placebo
- **DRUG:** BPL-1357

## Key facts

- **NCT ID:** NCT05027932
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-27
- **Primary completion:** 2023-06-13
- **Final completion:** 2025-02-25
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05027932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05027932, "Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05027932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*